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Sir,
Jessner’s lymphocytic infiltration of the skin (JLIS) is a 
skin condition of unknown aetiology characterized by er-
ythematous papules and plaques located on the head, neck 
and upper back. The eruption resolves spontaneous ly after 
months or a few years but can recur for several years. A 
variety of empirical treatments has been tried with limited 
success. We report here the first published case of JLIS 
successfully treated with methotrexate (MTX). 
CASE REPORT
A 41-year-old woman presented with a 3-year history of 
erythematous papules and plaques on both cheeks. The 
lesions were asymptomatic, without burning or pruritus, 
but cosmetically disfiguring. The patient denied onset or 
exacerbation of the eruption following sun exposure. Pre-
vious treatment included cryotherapy, pulsed-dye laser 
and potent topical steroids with little or no response.
Skin examination revealed multiple erythematous in-
filtrated papules and plaques with no epidermal changes 
on both cheeks (Fig. 1A). She had a few hypopigmented 
scars after earlier laser- or cryotherapy.
Full blood cell count, renal, liver and thyroid function, 
borrelia serology, screening for antinuclear antibody, 
anti-dsDNA antibody and antibodies to Ro and La were 
negative or normal, except for a recurrent leukocytosis 
(mostly neutrophilic) up to 19 × 109/l, often coincident 
with a flare in skin lesions.
Repeated skin biopsies demonstrated a normal 
epidermis with a dense perivascular and periadnexal 
infiltrate of lymphocytes in the reticular dermis, and 
mucin between collagen bundles (Fig. 2). Direct 
immuno fluorescense was not performed. In one biopsy 
the lympho cytic infiltration was more prominent than 
expected in JLIS. Immunohistochemistry showed a pre-
dominance of T cells, mostly CD4+ and a few CD20+ 
and CD79+ B cells, but without germinal centres. A 
diagnosis of lymphoma or pseudolymphoma was sug-
gested among the differential diagnoses. A computerized 
tomography scan of the thorax and abdomen revealed 
no suspicious lymph nodes. A bone marrow examination 
showed reactive changes with a slight leukocytosis.
The patient had a history of chronic obstructive pulmo-
nary disease (COPD) treated with seretide (GlaxoSmith-
Kline Pharma A/S, Brøndby, Denmark) (salmeterol, 
fluticasone) and short courses of prednisolone (Nycomed, 
Roskilde, Denmark) to a maximum of 30 mg daily. 
We started treatment with hydroxychloroquine 250 mg 
daily, and later treated her successively with tetra cycline 
500 mg twice daily, dapsone (Scanpharm A/S, Bir-
kerød, Denmark) 50 mg twice daily in combination with 
topical tacrolimus 0.1% ointment twice daily and sun 
protection creams. All the treatments proved ineffective. 
We noticed, however, that after a treatment course with 
prednisolone due to COPD, the skin changes regressed 
considerably, and some of the lesions disappeared for a 
period of time. Consequently, when her facial eruption 
recurred she was treated with prednisolone up to 30 mg 
daily, but the treatment had to be stopped due to severe 
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Fig. 1. Patient with Jessner’s lymphocytic infiltration of the skin (A) before 
treatment and (B) after treatment with methotrexate.
Fig. 2. Punch biopsy from the face. The epidermis is normal without 
inflammation at the dermo-epidermal interface. There are dense perivascular 
and periadnexal lymphocytic infiltrates and only sparse mucin between 
collagen bundles.
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Cushingoid features and osteopaenia. The patient was 
severely cosmetically disturbed and oral MTX 15 mg 
weekly was prescribed. The outpatient control performed 
2 months later showed that her facial skin changes had 
cleared completely (Fig. 1B) and the MTX treatment 
was stopped ater 4 months. No relapse occurred during 
2 years of observation.
DISCUSSION
JLIS, described by Jessner & Kanof in 1953 (1), is 
known as a benign chronic T-cell infiltrative disorder 
with lesions persisting for several months or years. 
Spontaneous remission may be seen, but JLIS has a 
tendency to relapse. For a period of 10 years, before the 
treatment with MTX, our patient experienced intermit-
tent remissions and relapses, and on several occasions 
almost complete resolution following treatment of her 
COPD with prednisolone, but with a fast post-treatment 
recurrence. 
The incidence of JLIS is unknown, but it is considered 
uncommon. It mostly affects middle-aged adults, with 
equal incidence in men and women, and very rarely 
occurs in children (2, 3). Familial occurrence has been 
described in the literature (4, 5). JLIS is characterized 
by single or multiple erythematous papules or plaques 
and, less commonly, nodules, typically localized on the 
face, neck, chest, arms and upper back (3). Sometimes 
an arciform configuration with central clearing is seen. 
Usually the lesions are asymptomatic, but they can be 
itching or burning. The relationship to sun exposure is 
variable and there is no regional variation in incidence 
(3). Whether JLIS is a separate entity, or belongs to the 
disease spectrum of cutaneous lupus erythematosus or 
polymorphous light eruption is still a matter of debate, 
since clinical and histopathological features may over-
lap in particular with lupus erythematosus tumidus. 
Recent comprehensive studies conclude that these two 
conditions share more similarities than differences (2, 
6). A few cases related to Borrelia burgdorferi infection 
or drugs have been reported (7, 8). Also, a few cases 
have been ascribed to contact allergy (9). 
Histopathologically JLIS is characterized by a su-
perficial and deep, primarily perivascular, sleeve-like 
lymphocytic dermal infiltrate with a predominance 
of small mature polyclonal lymphocytes and without 
epidermal involvement (2, 10). Deposits of mucin in 
the reticular dermis have been described (6). However, 
other authors have been unable to demonstrate mucin 
in JLIS (2, 11). 
A variety of treatments has been tried, with variable, 
and often limited, success, including topical, intra-
lesional or systemic corticosteroids, antimalarials, 
thalidomide, tetracyclines, cryotherapy and photo-
protection. A few cases of successful treatment with 
dapsone, auranofin, and chemotherapy have been re-
ported (12–14). Treatment with antimalarials is usually 
effective in cases with photo-sensitivity. In our case 
there was no response to antimalarials, perhaps because 
the patient was a smoker (15). After treatment with 
MTX, the skin changes disappeared completely and 
did not recur during the 2 years of observation. In our 
opinion, treatment with MTX may be a possibility in 
cases of refractory disease that do not respond to more 
established therapies. 
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